PHATHOM PHARMACEUTICALS INC's ticker is PHAT and the CUSIP is 71722W107. A total of 95 filers reported holding PHATHOM PHARMACEUTICALS INC in Q2 2022. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2022 | $288,000 | -37.9% | 34,100 | 0.0% | 0.24% | -17.3% |
| Q1 2022 | $464,000 | -30.8% | 34,100 | 0.0% | 0.28% | -29.2% |
| Q4 2021 | $671,000 | -38.7% | 34,100 | 0.0% | 0.40% | -38.2% |
| Q3 2021 | $1,094,000 | -5.2% | 34,100 | 0.0% | 0.65% | +42.0% |
| Q2 2021 | $1,154,000 | -9.9% | 34,100 | 0.0% | 0.46% | +5.1% |
| Q1 2021 | $1,281,000 | +12.3% | 34,100 | -0.7% | 0.44% | +9.3% |
| Q4 2020 | $1,141,000 | -10.5% | 34,350 | -1.2% | 0.40% | -32.5% |
| Q3 2020 | $1,275,000 | +11.5% | 34,776 | 0.0% | 0.59% | -44.7% |
| Q2 2020 | $1,144,000 | – | 34,776 | – | 1.07% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Medicxi Ventures Management (Jersey) Ltd | 3,760,869 | $39,000,212 | 12.45% |
| Frazier Life Sciences Management, L.P. | 10,109,279 | $104,833,223 | 6.96% |
| Decheng Capital Management III (Cayman), LLC | 850,000 | $8,814,500 | 2.94% |
| Carlyle Group Inc. | 3,496,808 | $36,191,963 | 1.57% |
| Ghost Tree Capital, LLC | 395,000 | $4,096,150 | 1.35% |
| Newtyn Management, LLC | 500,000 | $5,185,000 | 1.28% |
| Altium Capital Management LP | 220,000 | $2,281,400 | 1.19% |
| StepStone Group LP | 422,085 | $4,377,021 | 0.98% |
| MPM BioImpact LLC | 347,332 | $3,601,833 | 0.96% |
| NEA Management Company, LLC | 1,276,595 | $12,238,290 | 0.94% |